ORIGINAL ARTICLE

Imprinting, expression, and localisation of DLK1 in Wilms tumours

R Fukuzawa, R W Heathcott, I M Morison and A E Reeve

Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, PO Box 56, Dunedin, New Zealand

Correspondence to:
Correspondence to:
Dr R Fukuzawa
Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, PO Box 56, Dunedin, New Zealand; ryuji.fukuzawa{at}stonebow.otago.ac.nz

Background: Loss of imprinting (LOI) of the H19/IGF2 domain is a common feature of Wilms tumour. The GTL2/DLK1 domain is also imprinted and is structurally similar to H19/IGF2. The question arises as to whether DLK1 also undergoes LOI in Wilms tumour, or whether the LOI mechanism is restricted to the H19/IGF2 domain.

Aim: To investigate the imprinting status of DLK1 in Wilms tumours with IGF2 LOI. The cellular localisation of DLK1 in the tumours was also examined.

Methods: DLK1 expression was measured by quantitative real time polymerase chain reaction (Q-PCR) in 30 Wilms tumours that had previously been classified according to whether they had IGF2 LOI, WT1 mutations, or 11p15.5 loss of heterozygosity. Allele specific expression of DLK1 was examined by direct sequencing using a DLK1 exon 5 polymorphism (rs1802710). Immunohistochemical analysis of DLK1 was performed on 13 tumours and two intralobar nephrogenic rests, in addition to two fetal kidneys and one fetal skeletal muscle sample.

Results: Ten of 30 tumours were heterozygous for rs1802710 and all tumours showed retention of imprinting of DLK1. Moderate to high expression of DLK1 was detected by Q-PCR in nine of 13 tumours with myogenic differentiation. Immunohistochemical expression of DLK1 was detected in the myogenic elements.

Conclusion: LOI does not occur at the GTL2/DLK1 domain in Wilms tumour. This finding suggests that LOI at 11p15.5 does not reflect non-specific disruption of a shared imprinting mechanism. DLK1 expression in Wilms tumour might reflect the presence of myogenic differentiation, rather than an alteration of its imprinting status.

Abbreviations: BSA, bovine serum albumin; DMR, differentially methylated region; ILNR, intralobar nephrogenic rest; LOH, loss of heterozygosity; LOI, loss of imprinting; PBS, phosphate buffered saline; PCR, polymerase chain reaction; Q-PCR, quantitative real time polymerase chain reaction

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Brown, K. W., Power, F., Moore, B., Charles, A. K., Malik, K. T.A. (2008). Frequency and Timing of Loss of Imprinting at 11p13 and 11p15 in Wilms' Tumor Development. Mol Cancer Res 6: 1114-1123 [Abstract] [Full Text]  
• Huang, J., Zhang, X., Zhang, M., Zhu, J.-D., Zhang, Y.-L., Lin, Y., Wang, K.-S., Qi, X.-F., Zhang, Q., Liu, G.-Z., Yu, J., Cui, Y., Yang, P.-Y., Wang, Z.-Q., Han, Z.-G. (2007). Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis 28: 1094-1103 [Abstract] [Full Text]  
• Kawakami, T., Chano, T., Minami, K., Okabe, H., Okada, Y., Okamoto, K. (2006). Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum Mol Genet 15: 821-830 [Abstract] [Full Text]